Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL

Affiliations

• ¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
• ² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China.
• ³ Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, People's Republic of China.
• ⁴ Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, People's Republic of China.
• ⁵ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. [email protected].
• ⁶ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China. [email protected].
• ⁷ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. [email protected].
• ⁸ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China. [email protected].
• ⁹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. [email protected].
• ¹⁰ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, 215000, Suzhou, People's Republic of China. [email protected].